Cytogenetic effects of antidiabetic drug metformin

References

• Aleisa, A.M., et al., 2007. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice. Mutation Research, 634 (1–2), 93–100.
   PubMed Web of Science ®Google Scholar
• Algire, C., et al., 2012. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prevention Research (Philadelphia, PA.), 5 (4), 536–543.
   PubMed Web of Science ®Google Scholar
• Amador, R.R., et al., 2012. Metformin (dimethyl-biguanide) induced DNA damage in mammalian cells. Genetics and Molecular Biology, 35 (1), 153–158.
   PubMed Web of Science ®Google Scholar
• Anisimov, V.N., et al., 2005. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology, 40 (8–9), 685–693.
   PubMed Web of Science ®Google Scholar
• Ataseven, N., et al., 2016. Genotoxicity of monosodium glutamate. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 91, 8–18.
   PubMed Web of Science ®Google Scholar
• Attia, S.M., Helal, G.K., and Alhaider, A.A., 2009. Assessment of genomic instability in normal and diabetic rats treated with metformin. Chemico-Biological Interactions, 180 (2), 296–304.
   PubMed Web of Science ®Google Scholar
• Bailey, C.J., and Turner, R.C., 1996. Metformin. The New England Journal of Medicine, 334 (9), 574–579.
   PubMed Web of Science ®Google Scholar
• Bando, K., et al., 2010. Comparison of potential risks of lactic acidosis induction by biguanides in rats. Regulatory Toxicology and Pharmacology : RTP, 58 (1), 155–160.
   PubMed Web of Science ®Google Scholar
• Biswas, S.J., Pathak, S., and Khuda-Bukhsh, A.R., 2004. Assessment of the genotoxic and cytotoxic potential of an anti-epileptic drug, phenobarbital, in mice: a timecourse study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 563 (1), 1–11.
   PubMed Web of Science ®Google Scholar
• Bonassi, S., et al., 2011. Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis, 26 (1), 93–100.
   PubMed Web of Science ®Google Scholar
• Brunton, S.A., 2011. Intensifying type 2 diabetes therapy: assessing the options. The Journal of Family Practice, 60 (9 Suppl), S3.
   PubMedGoogle Scholar
• Chandirasekar, R., et al., 2014. Assessment of genotoxic and molecular mechanisms of cancer risk in smoking and smokeless tobacco users. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 767, 21–27.
   PubMed Web of Science ®Google Scholar
• Cheki, M., et al., 2019. Metformin attenuates cisplatin-induced genotoxicity and apoptosis in rat bone marrow cells. Drug and Chemical Toxicology, 1–8. doi:https://doi.org/10.1080/01480545.2019.1609024.
   Web of Science ®Google Scholar
• Cheki, M., et al., 2016. The radioprotective effect of metformin against cytotoxicity and genotoxicity induced by ionizing radiation in cultured human blood lymphocytes. Mutation Research, 809, 24–32.
   PubMed Web of Science ®Google Scholar
• Cheng, A.Y., and Fantus, I.G., 2005. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 172 (2), 213–226.
   PubMed Web of Science ®Google Scholar
• Collins, A.R., 2004. The comet assay for DNA damage and repair: principles, applications, and limitations. Molecular Biotechnology, 26 (3), 249–261.
   PubMed Web of Science ®Google Scholar
• Collins, A.R., 2015. Commentary the comet assay: a heavenly method! Mutagenesis, 30 (1), 1–4.
   PubMed Web of Science ®Google Scholar
• Currie, C.J., Poole, C.D., and Gale, E.A., 2009. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 52 (9), 1766–1777.
   PubMed Web of Science ®Google Scholar
• Evans, H. J., 1984. Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagenesis in mutagen tests. In: B.J. Kilbey, M. Legator, W. Nichols and C. Ramel, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier Science Publishers, 405–427.
   Google Scholar
• Evans, J.M., et al., 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ (Clinical Research ed.), 330 (7503), 1304–1305.
   PubMed Web of Science ®Google Scholar
• Fei, C., et al., 2015. Safety evaluation of a triazine compound nitromezuril by assessing bacterial reverse mutation, sperm abnormalities, micronucleus and chromosomal aberration. Regulatory Toxicology and Pharmacology : RTP, 71 (3), 585–589.
   PubMed Web of Science ®Google Scholar
• Fenech, M., 2000. The in vitro micronucleus technique. Mutation Research, 455 (1–2), 81–95.
   PubMed Web of Science ®Google Scholar
• Garg, G., et al., 2017. Metformin alleviates altered erythrocyte redox status during aging in rats. Rejuvenation Research, 20 (1), 15–24.
   PubMed Web of Science ®Google Scholar
• Ginzkey, C., et al., 2014. Nicotine derived genotoxic effects in human primary parotid gland cells as assessed in vitro by comet assay, cytokinesis-block micronucleus test and chromosome aberrations test. Toxicology In Vitro : An International Journal Published in Association with BIBRA, 28 (5), 838–846.
   PubMed Web of Science ®Google Scholar
• Giovannucci, E., et al., 2010. Diabetes and cancer: a consensus report. Diabetes Care, 33 (7), 1674–1685.
   PubMed Web of Science ®Google Scholar
• Guariguata, L., et al., 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice, 103 (2), 137–149.
   PubMed Web of Science ®Google Scholar
• Gul, O.O., et al., 2013. Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study. Mutation Research, 757 (1), 31–35.
   PubMed Web of Science ®Google Scholar
• Hagmar, L., et al., 1998. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European study group on cytogenetic biomarkers and health (ESCH). Cancer Research, 58 (18), 4117–4121.
   PubMed Web of Science ®Google Scholar
• Huerta, I., et al., 2014. Genotoxic evaluation of five Angiotesin II receptor blockers: in vivo and in vitro micronucleus assay. Mutation Research. Genetic Toxicology and Environmental Mutagenesis, 767, 1–7.
   PubMed Web of Science ®Google Scholar
• Ighodaro, O.M., 2018. Molecular pathways associated with oxidative stress in diabetes mellitus. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 108, 656–662.
   PubMed Web of Science ®Google Scholar
• Inzucchi, S.E., et al., 2012. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35 (6), 1364–1379.
   PubMed Web of Science ®Google Scholar
• Kanto, K., et al., 2018. Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 9 (3), 587–593.
   Web of Science ®Google Scholar
• Kolivand, S., et al., 2017. The anti-apoptotic mechanism of metformin against apoptosis induced by ionizing radiation in human peripheral blood mononuclear cells. Klinicka Onkologie : casopis Ceske a Slovenske Onkologicke Spolecnosti, 30 (5), 372–379.
   PubMedGoogle Scholar
• Koritzinsky, M., 2015. Metformin: a novel biological modifier of tumor response to radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 93 (2), 454–464.
   PubMed Web of Science ®Google Scholar
• Lebovitz, H. E., 2005. Management of hyperglycemia with oral antihyperglycemic agents in Type 2 diabetes. In: C.R. Kahn, G.C. Weir, G.L. King, A.M. Jacobson, and A.C. Moses, eds. Joslin’s Diabetes Mallitus, Vol 41. Boston: Lipincott Williams & Wilkins, 687–710.
   Google Scholar
• León-Mejíaa, G., et al., 2019. Cytotoxic and genotoxic effects in mechanics occupationally exposed to diesel engine exhaust. Ecotoxicology and Environmental Safety, 171, 264–273.
   PubMed Web of Science ®Google Scholar
• Mamur, S., et al., 2020. Evaluation of the cytotoxic and genotoxic effects of mycotoxin fusaric acid. Drug and Chemical Toxicology, 43 (2), 149–157.
   PubMed Web of Science ®Google Scholar
• Mamur, S., et al., 2018. Assessment of cytotoxic and genotoxic effects of enniatin-A in vitro. Food Additives and Contaminants Part A, 35 (8), 1633–1644.
   PubMed Web of Science ®Google Scholar
• Najafi, M., et al., 2018. Metformin: prevention of genomic instability and cancer: a review. Mutation Research. Genetic Toxicology and Environmental Mutagenesis, 827, 1–8.
   PubMed Web of Science ®Google Scholar
• Nathan, D.M., et al., 2009. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32 (1), 193–203.
   PubMed Web of Science ®Google Scholar
• Norppa, H., et al., 2006. Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 600 (1–2), 37–45.
   PubMed Web of Science ®Google Scholar
• Noto, H., et al., 2012. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. Public Library of Science, 7 (3), e33411.
   Google Scholar
• Onaran, I., et al., 2006. Metformin does not prevent DNA damage in lymphocytes despite its antioxidant properties against cumene hydroperoxide-induced oxidative stress. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 611 (1–2), 1–8.
   PubMed Web of Science ®Google Scholar
• Palus, J., et al., 2003. Genotoxic effects of occupational exposure to lead and cadmium. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 540 (1), 19–28.
   PubMed Web of Science ®Google Scholar
• Perez-Fernandez, R., et al., 2013. Structure and thermodynamical properties of metformin salicylate. Crystal Growth & Design, 13 (4), 1780–1785.
   Web of Science ®Google Scholar
• Perry, P. E., and Thompson, E. J., 1984. The methodology of sister chromatid exchanges. In: B.J. Kilbey, M. Legator, W. Nichols, C. Ramel, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier Science Publishers, 495–529.
   Google Scholar
• Rabbani, S.I., Devi, K., and Khanam, S., 2010. Role of pioglitazone with metformin or glimepiride on oxidative stress-induced nuclear damage and reproductive toxicity in diabetic rats. The Malaysian Journal of Medical Sciences, 17, 3–11.
   PubMedGoogle Scholar
• Radziuk, J., et al., 2003. Metformin and its liver targets in the treatment of type 2 diabetes. Current Drug Targets. Immune, Endocrine and Metabolic Disorders, 3 (2), 151–169.
   PubMedGoogle Scholar
• Rizos, C.V., and Elisaf, M.S., 2013. Metformin and cancer. European Journal of Pharmacology, 705 (1–3), 96–108.
   PubMed Web of Science ®Google Scholar
• Rojas, L.B., and Gomes, M.B., 2013. Metformin: an old but still the best treatment for type 2 diabetes. Diabetes & Metabolic Syndrome, 5 (1), 6.
   Web of Science ®Google Scholar
• Sahra, I.B., et al., 2008. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27 (25), 3576–3586.
   PubMed Web of Science ®Google Scholar
• Sant’Anna, J.R., et al., 2013. Metformin’s performance in vitro and in vivo genetic toxicology studies. Experimental Biology and Medicine, 238 (7), 803–810.
   Web of Science ®Google Scholar
• Schafer, G., 1983. Biguanides. A review of history, pharmacodynamics, and therapy. Diabetes & Metabolism, 9 (2), 148–163.
   Web of Science ®Google Scholar
• Schneider, E.L., et al., 1981. Simultaneous examination of sister-chromatid exchanges and cell replication kinetics in tumor and normal cells in vivo. Cancer Reserach, 41, 4973–4975.
   Google Scholar
• Schneider, M.B., et al., 2001. Prevention of pancreatic cancer in hamsters by metformin. Gastroenterology, 120 (5), 1263–1270.
   PubMed Web of Science ®Google Scholar
• Singh, N.P., et al., 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research, 175 (1), 184–191.
   PubMed Web of Science ®Google Scholar
• Sivikova, K., et al., 2018. Potential chromosome damage, cell-cycle kinetics/and apoptosis induced by epoxiconazole in bovine peripheral lymphocytes in vitro. Chemosphere, 193, 82–88.
   PubMed Web of Science ®Google Scholar
• Speit, G., and Henderson, L., 2005. Review of the in vivo genotoxicity tests performed with styrene. Mutation Research, 589 (1), 67–79.
   PubMed Web of Science ®Google Scholar
• Speit, G., and Houpter, S., 1985. On the mechanism of differential Giemsa staining of Bromodeoxyuridine substitute chromosomes. II. Differences between the demonstrations of sister chromatid differentiation and replication patterns. Human Genetics, 70 (2), 126–129.
   PubMed Web of Science ®Google Scholar
• Surrallés, J., et al., 1995. Induction of micronuclei by five pyrethroid insecticides in whole blood and isolated human lymphocytes cultures. Mutation Research, 341 (3), 169–184.
   PubMed Web of Science ®Google Scholar
• Tokajuk, A., et al., 2015. Antidiabetic drugs and risk of cancer. Pharmacological Reports : PR, 67 (6), 1240–1250.
   PubMed Web of Science ®Google Scholar
• Turacli, I.D., et al., 2018. Potential effects of metformin in DNA BER system based on oxidative status in type 2 diabetes. Biochimie, 154, 62–68.
   PubMed Web of Science ®Google Scholar
• Ullah, A., et al., 2016. Enhancement of anti-proliferative activities of Metformin, when combined with Celecoxib, without increasing DNA damage. Environmental Toxicology and Pharmacology, 45, 227–234.
   PubMed Web of Science ®Google Scholar
• Unal, F., et al., 2016. Answer to letter sent by Dr. M.D. Rogers (Chairman of the International Glutamate Technical Committee (IGTC), Belgium) related to Ataseven et al. article published in Food and Chemical Toxicology 2016; 91:8–18. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 94, 262–267.
   PubMed Web of Science ®Google Scholar
• Url 1: Medical Officer Safety Review of an Original NDA Submission, NDA 20-357 Metformin. https://diabetes-mellitus.org/metform.pdf
   Google Scholar
• Viollet, B., et al., 2012. Cellular and molecular mechanisms of metformin: an overview. Clinical Science (London, England : 1979), 122 (6), 253–270.
   PubMed Web of Science ®Google Scholar
• Yang, X., et al., 2017. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. Biochimica et Biophysica Acta. Molecular Basis of Disease, 1863 (8), 1984–1990.
   PubMed Web of Science ®Google Scholar
• Yuzbasioglu, D.,et al..l, 2018. Investigation of in vitro genotoxic effects of an anti-diabetic drug sitagliptin. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 112, 235–241.
   PubMed Web of Science ®Google Scholar
• Zhang, Z.J., et al., 2011. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care, 34 (10), 2323–2328.
   PubMed Web of Science ®Google Scholar
• Zhou, T., et al., 2018. A preclinical overview of metformin for the treatment of type 2 diabetes. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 106, 1227–1235.
   PubMed Web of Science ®Google Scholar